TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01769196
Drug: Simtuzumab
Normalized name: Simtuzumab
DrugBank: Simtuzumab (DB12152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/mL single-dose vials administered subcutaneously once a week
Study: NCT01769196
Drug: Simtuzumab placebo
DrugBank: Simtuzumab (DB12152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simtuzumab placebo single-dose vials administered subcutaneously once a week
Study: NCT00627367
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
Study: NCT03646370
Drug: Tenofovir Alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
Study: NCT00308269
Drug: Vintafolide IV Bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Vintafolide (DB05168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
Study: NCT00308269
Drug: Vintafolide IV Infusion
Normalized name: Duo Fusion
DrugBank: Vintafolide (DB05168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
Study: NCT03675139
Drug: Medroxyprogesterone Acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At a dosage of 10mg/day
Study: NCT03675139
Drug: Dydrogesterone 10 MG
Normalized name: dydrogesterone 10 MG
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At a dosage of 20 mg/day
Study: NCT01756417
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
Study: NCT01756417
Drug: Canagliflozin (JNJ-28431754)
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
Study: NCT04055909
Drug: nangibotide low dose
Normalized name: ethinyl estradiol
DrugBank: Nangibotide (DB16247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nangibotide 0.3 mg/kg/h
Study: NCT04055909
Drug: nangibotide high dose
Normalized name: high-density polyethylene
DrugBank: Nangibotide (DB16247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nangibotide 1.0 mg/kg/h
Study: NCT00196365
Drug: levonorgestrel/EE 0.15/0.03 mg tablets and placebo
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet daily
Study: NCT03960658
Drug: ketamine-enhanced prolonged exposure
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
Study: NCT00904488
Drug: Addition of oral Metolazone
Normalized name: Metolazone
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
Study: NCT00904488
Drug: Furosemide dose escalation
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
Study: NCT02445326
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03005548
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning.
Study: NCT00536471
Drug: Duloxetine hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03458780
Drug: Yellow Fever Vaccine
Normalized name: yellow fever vaccine
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow Fever Vaccine .5 ml
Study: NCT00533039
Drug: Varespladib (A-002)
Normalized name: Varespladib
DrugBank: Varespladib (DB11909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
Study: NCT00520104
Drug: intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug interaction
Study: NCT00036634
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir DF tablet administered orally once daily
Study: NCT00036634
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide tablet(s) administered orally once daily
Study: NCT01903018
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193206
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
Study: NCT00193206
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
Study: NCT04258371
Drug: Dapagliflozin 10 MG
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
Study: NCT00474669
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
Study: NCT02952001
Drug: 4 mg CLS-TA Suprachoriodal Injection
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
Study: NCT00193206
Drug: Albumin-bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
Study: NCT01873716
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
Study: NCT00695617
Drug: trisodiumcitrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: trisodiumcitrate 1.035 M
Study: NCT01500850
Drug: human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal
Study: NCT01500850
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Study: NCT01500850
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal
Study: NCT02047214
Drug: TPI 287
Normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
Study: NCT02047214
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
Study: NCT01969955
Drug: nanoparticle albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
Study: NCT01364519
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dry powder for inhalation, Single Dose, 500mcg
Study: NCT01364519
Drug: Placebo for Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dry powder for inhalation, Single Dose, placebo
Study: NCT00390611
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00390611
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel
Study: NCT00390611
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin
Study: NCT01709370
Drug: Letrozole, PD 0332991
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00450892
Drug: docetaxel+lapatinib
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
Study: NCT00450892
Drug: docetaxel + trastuzumab
Normalized name: Docetaxel
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
Study: NCT00450892
Drug: docetaxel + trastuzumab + lapatinib
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100
Study: NCT00140166
Drug: niacinamide
Normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00140166
Drug: ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01343173
Drug: Imatinib stop
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To stop imatinib after inclusion.
Study: NCT00364442
Drug: fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: investigational drug
Study: NCT00006036
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006036
Drug: lurtotecan liposome
Normalized name: Lurtotecan
DrugBank: Lurtotecan (DB12222)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02604225
Drug: Methoxyflurane
Normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
Study: NCT00257686
Drug: Pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02282280
Drug: Prilocaine Chlorhydrate
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of prilocaine in spinal anesthesia
Study: NCT01281007
Drug: Famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir 125 mg every 12 hours for 5 days
Study: NCT01281007
Drug: Aciclovir
Normalized name: Aciclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aciclovir 200 mg every 4 hours fo 5 days
Study: NCT00281021
Drug: Erlotinib plus Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive erlotinib and digoxin daily until progression.
Study: NCT00140231
Drug: r-metHuLeptin
Normalized name: r-metHuLeptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: recombinant human leptin
Study: NCT03356678
Drug: Pralatrexate
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~* Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed.
Study: NCT01753154
Drug: Solution B (balance PD solution)
Normalized name: carbinoxamine maleate Oral Solution [Carbinoxamine PD]
DrugBank: Carbinoxamine (DB00748)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
Study: NCT01753154
Drug: Solution A (conventional PD solution)
Normalized name: naphazoline / pheniramine Ophthalmic Solution [Naphcon A]
DrugBank: Pheniramine (DB01620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
Study: NCT04298463
Drug: Xydalba
DrugBank: Dalbavancin (DB06219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drugs were administered i.v.
Study: NCT04298463
Drug: vancomycin, teicoplanin or daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs were administered i.v.
Study: NCT00402363
Drug: omega-3-acid ethyl esters
Normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00638612
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
Study: NCT01800357
Drug: infusion of mildronate
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion of mildronate(500mg) once a day and for 14 days
Study: NCT01800357
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion of aspirin (100mg) once a day for days
Study: NCT01189695
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir 200/50 mg every 12 hours
Study: NCT01080846
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mcg of sublingual misoprostol
Study: NCT01594866
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: escitalopram 20mg and 30mg p.o. daily, 6 weeks
Study: NCT01594866
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
Study: NCT00194766
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
Study: NCT01758263
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol, oral administration
Study: NCT01758263
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol, oral administration
Study: NCT04645004
Drug: Aspirin 81Mg Non-enteric coated Tab
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tab daily
Study: NCT00729963
Drug: Sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.
Study: NCT00677248
Drug: Ezetimibe and placebo
Normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo or three different doses of eprotirome added to ezetimibe treatment
Study: NCT00726232
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
Study: NCT00677248
Drug: Eprotirome and ezetimibe
Normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo or three different doses of eprotirome added to ezetimibe treatment
Study: NCT02454205
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
Study: NCT02454205
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg po daily for 2 weeks, followed by 200mg three times per week .
Study: NCT02454205
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750mg (\<50kg) 1000mg (\>50kg)
Study: NCT02454205
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
Study: NCT02454205
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
Study: NCT02454205
Drug: Ethionamide
Normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/kg (max 900mg)
Study: NCT02454205
Drug: Terizidone
Normalized name: terizidone
DrugBank: Terizidone (DB12954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750mg (40-70kg) 750-1000mg (71-90kg)
Study: NCT02454205
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg po daily.
Study: NCT02396979
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03819010
Drug: Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
Study: NCT03266406
Drug: Hyaluronidase
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
Study: NCT01379287
Drug: Iso-Fludelone
Normalized name: ISO-Fludelone
DrugBank: KOSN-1724 (DB13078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
Study: NCT02300051
Drug: TAU
Normalized name: Tauvid
DrugBank: Flortaucipir F-18 (DB14914)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00701207
Drug: nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
Study: NCT03257033
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03257033
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy
Study: NCT00003202
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003202
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00398840
Drug: ARQ 171
Normalized name: ARQ 171
DrugBank: ARQ 171 (DB06034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00757055
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate \< 60 bpm.
Study: NCT00748371
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
Study: NCT00748371
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1300mg aspirin: one 650-mg capsule by mouth twice daily